Jordyn Sava is an editor for Targeted Oncology.
Trilaciclib Administered Prior to Sacituzumab Reduces Adverse Events in TNBC
November 2nd 2022Phase 2 trial of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced, or metastatic triple-negative breast cancer demonstrates encouraging reductions in adverse events.
KEYNOTE B10 Evaluates New Triplet Regimen for Patients With HNSCC
November 1st 2022In an interview with Targeted Oncology, Marcin Dzienis, MD, further discussed the phase 4 trial of pembrolizumab plus carboplatin and paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Luspatercept Improves RBC Transfusion Independence in Patients With MDS
October 31st 2022In the prespecified interim analysis of the COMMANDS trial for low-risk myelodysplastic syndromes, luspatercept had statistically significant and clinically meaningful improvements in red blood cell transfusion independence with no new safety signals.
ODAC Votes Against Omburtamab for Neuroblastoma with CNS/ Leptomeningeal Metastases
October 28th 2022In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.
LIGHTHOUSE Study Further Confirms Benefit of Melphalan Flufenamide in R/R Multiple Myeloma
October 27th 2022Despite the small number of patients enrolled, the confirmatory phase 3 LIGHTHOUSE study of melphalan flufenamide in patients with relapsed/refractory multiple myeloma demonstrates promising safety and efficacy.
Special Episode: Managing Cardiotoxicity from ICI Therapy in Patients With Cancer
October 25th 2022In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, and Chris Fine, MD, FACC, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.
Allogeneic CAR T-Cell Therapy May Provide Alternate Options in ALL
October 24th 2022In an interview with Targeted Oncology, Nitin Jain, MD, further discussed the ongoing research of allogeneic chimeric antigen receptor T cells as treatment for patients with ALL. He also notes what future research must examine to further the field.
Exploring Non-Intensive Treatment Options for Elderly/Unfit Patients With AML
October 22nd 2022In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed the changes seen in the treatment landscape for patients with acute myeloid leukemia, specifically highlighting elderly and/or unfit patients.